FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma By Ogkologos - August 22, 2025 402 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR 11 Sun Safety Myths Debunked July 16, 2021 Genetic Cancer Screenings in Younger Women May Be Cost-Effective and Lead... November 26, 2020 Paralyzed Bride Walks Down Aisle At Her Wedding & Surprises Groom November 20, 2021 Frederick National Laboratory for Cancer Research: A Unique Resource for the... March 28, 2023 Load more HOT NEWS Autumn and Letting Go Predicting future breast cancer with precision Signal of Increased Risk of Major Cardiovascular Events and Cancer with... Young Breast Cancer Survivors Without a Germline Pathogenic Variant Have a...
